Figure 1.

Schematic view of T cell-redirecting therapies

The T cell receptor (TCR) complex, composed of two TCR chains (α/β or γ/δ) and six CD3 chains, recognizes peptides presented by the MHC on the target cell. A chimeric antigen receptor (CAR) contains an antigen-binding domain (typically a single-chain variable fragment [scFv]) fused to a co-stimulatory domain (such as CD28 or 4-1BB) and a CD3ζ signaling domain. TCEs: bispecific antibodies or bispecific TCEs (BiTEs) target a tumor antigen and CD3 simultaneously to activate and redirect T cells to tumor cells.